Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
ARTV Stock Chart & Stats
$6.67
$0.32(3.02%)
At close: 4:00 PM EST
$6.67
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$1.47 - $7.75
Previous CloseN/A
Volume23.16K
Average Volume (3M)176.85K
Market Cap
$164.86M
Enterprise Value$149.10M
Total Cash (Recent Filing)$108.01M
Total Debt (Recent Filing)$10.94M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 07, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding24,716,673
10 Day Avg. Volume132,684
30 Day Avg. Volume176,850
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-112.28
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$17.00Price Target Upside154.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ReadoutsClinical timelines for initial activity data in rheumatoid arthritis patients remain on track, supporting the analyst's recommendation for program momentum.
Manufacturing And CostAlloNK's allogeneic, non‑engineered design enables off‑the‑shelf availability and lower manufacturing complexity, which could facilitate broader adoption in rheumatoid arthritis care.
Safety And Outpatient UseFavorable safety profile with minimal serious cell-therapy toxicities could allow outpatient administration and use in community treatment centers, improving potential access.
Bears Say
Limited Patient DataInitial efficacy observations are based on just over fifteen refractory patients, so conclusions remain preliminary and depend on confirmatory evidence from larger cohorts.
Pivotal Trial Size And CostA pivotal rheumatoid arthritis trial may require substantially more patients than smaller autoimmune studies, and a randomized control arm would increase trial complexity and development costs.
Regulatory And Evidentiary RiskRequirement for sufficient follow-up and confirmatory studies raises the risk that regulatory acceptance and market access could be delayed if initial results are not replicated.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $7.75 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $164.86M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 29 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Mar 10, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.847 by -$0.003.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,716,673 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.847. Following the earnings report the stock price went up 17.27%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (154.87% Upside)
$17.00 (154.87% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
198.77%
12-Months-Change
Fundamentals
Return on Equity
-60.22%
Trailing 12-Months
Asset Growth
-35.79%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$17.00
▲(154.87% Upside)
Technical Analysis
Ownership Overview
14.80% Insiders
2.16% Mutual Funds
60.52% Other Institutional Investors
21.52% Public Companies and Individual Investors
Options Prices
Currently, No data available
---